NCT00091143View on ClinicalTrials.gov

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

keyhole limpet hemocyanin

DRUG

fludarabine phosphate

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (1)

97213-2967

Providence Cancer Center at Providence Portland Medical Center, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

NCT00091143 - Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter